Skip to main content
. 2020 Oct 28;26(2):e316–e326. doi: 10.1002/onco.13552

Figure 3.

Figure 3

Management of fibroblast growth factor receptor‐related adverse events. (A): Nail changes. (B): Other dermatologic events. *Referral to a dermatologist for consultation is recommended for grade 3 and intolerable grade 2 events, or grade 2 events that have not responded to 4 weeks of therapy. Abbreviations: OTC, over the counter; PPES, palmar–plantar erythrodysesthesia syndrome; PRN, as needed; TMP/SMX DS, trimethoprim/sulfamethoxazole double strength.